A team of scientists using technology from the Swiss company Humabs BioMed SA has isolated an antibody from a patient infected with the Middle East Respiratory Syndrome (MERS) coronavirus, which has been found to be effective in mice. The findings were reported by Davide Corti, Humabs’ chief scientific officer, and colleagues on 27 July in Proceedings of the National Academy of Sciences.
